Compare Recursion Pharmaceuticals Inc (RXRX) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs ProShares UltraPro S&P500 — how do they compare? Recursion Pharmaceuticals Inc trades at $3.93 (market cap $2.14B), while ProShares UltraPro S&P500 trades at $154.16 (market cap $5.55B). The key difference: ProShares UltraPro S&P500 is far larger — about 2.6× Recursion Pharmaceuticals Inc's market cap, and ProShares UltraPro S&P500 is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and ProShares UltraPro S&P500 for 29 Days on average.
| RXRX | UPRO | |
|---|---|---|
Market Cap | $2.14B | $5.55B |
Volume | 30,789,535 | 2,078,694 |
Sector | Health | Leveraged / Inverse |
52-Week High | $6.79 | $157.66 |
52-Week Low | $2.84 | $89.29 |
Typical Hold Time | 22 Days | 29 Days |
Enterprise Value | $1.66B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
UPRO trades at $155.21, down 0.77% for the day, with technical indicators showing a bullish trend supported by moving averages while oscillators remain neutral. The stock faces resistance near $156-$160 with support at $151-$147. Recent news highlights S&P 500 valuation concerns and projected earnings growth slowdown from 35% in 2026 to 15% in 2027, creating mixed sentiment around leveraged ETF performance.
Outlook remains cautiously optimistic given the bullish technical setup, though leveraged nature amplifies risks from market volatility and earnings growth deceleration. Key opportunities include potential year-end rally patterns, while risks center on concentrated market exposure and macroeconomic headwinds affecting the underlying index performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
